Silence Therapeutics is a biotechnology company focused on discovering and developing molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with unmet medical need. Co.'s wholly owned pipeline is focused in three therapeutic areas of unmet need: cardiovascular disease, hematology and rare diseases. Co.'s wholly owned product candidates are: SLN360, which is an siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood; and SLN124, which is an siRNA molecule designed to treat erythropoiesis. The SLN average annual return since 2020 is shown above.
The Average Annual Return on the SLN average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SLN average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SLN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|